LifeStance Health Group, Inc. $LFST Shares Newly Purchased by Summit Creek Advisors LLC

Key Points

• Summit Creek Advisors initiated a position in LifeStance Health Group, buying 200,147 shares worth approximately $2.4 million in the third quarter, or about 0.05% of the company.
• LifeStance’s latest quarter beat expectations, with earnings of $0.06 per share versus $0.04 expected and revenue of $455.9 million versus $431.6 million forecast; revenue grew 25.3% year over year, and the company raised its full-year outlook.
• Analyst sentiment was broadly positive, with several firms raising price targets, though insiders have recently sold shares: reported sales over 90 days totaled about $146.4 million.

Summit Creek Advisors LLC bought a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 200,147 shares of the company's stock, valued at approximately $2,408,000. Summit Creek Advisors LLC owned about 0.05% of LifeStance Health Group at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new position in LifeStance Health Group in the 2nd quarter worth $389,293,000. Dimensional Fund Advisors LP raised its position in shares of LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company's stock valued at $66,038,000 after buying an additional 1,461,215 shares during the last quarter. Jennison Associates LLC increased its holdings in LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company's stock valued at $65,157,000 after acquiring an additional 2,843,388 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of LifeStance Health Group during the second quarter valued at about $30,881,000. Finally, Bank of America Corp DE bought a new stake in shares of LifeStance Health Group in the second quarter worth about $14,987,000. Institutional investors own 85.50% of the company's stock.

LifeStance Health Group Trading Up 2.5%

Shares of NASDAQ LFST opened at $13.77 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.38 and a current ratio of 1.44. The business's 50 day moving average price is $12.62 and its 200-day moving average price is $9.49. LifeStance Health Group, Inc. has a fifty-two week low of $5.87 and a fifty-two week high of $15.66. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 72.48 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.02. The company had revenue of $455.86 million during the quarter, compared to analysts' expectations of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The company's revenue was up 25.3% on a year-over-year basis. On average, sell-side analysts expect that LifeStance Health Group, Inc. will post 0.17 earnings per share for the current year.

LifeStance Health Group News Roundup

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
• Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

Insider Activity

In related news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the transaction, the insider owned 98,101,407 shares of the company's stock, valued at $1,041,836,942.34. This trade represents a 12.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CTO Vukasin Paunovich sold 42,067 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total transaction of $541,402.29. Following the completion of the transaction, the chief technology officer directly owned 205,379 shares in the company, valued at $2,643,227.73. This represents a 17.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 13,777,580 shares of company stock valued at $146,433,781. 3.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Barclays boosted their target price on LifeStance Health Group from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Thursday, September 10th. BTIG Research upped their price objective on LifeStance Health Group from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday. Wall Street Zen lowered LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 5th. KeyCorp lifted their target price on LifeStance Health Group from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Friday. Finally, Canaccord Genuity Group boosted their target price on LifeStance Health Group from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $13.75.

About LifeStance Health Group

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance's services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.